# Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

> **NCT05878184** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sana Biotechnology** · enrollment: 16 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** SC291

## Key facts

- **NCT ID:** NCT05878184
- **Lead sponsor:** Sana Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-02
- **Primary completion:** 2025-11-04
- **Final completion:** 2038-11-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05878184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05878184, "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05878184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*